PharmiWeb.com - Global Pharma News & Resources
07-Feb-2019

Global PD-1 and PD-L1 Inhibitors Markets, 2019-2023 - Special Drug Designations to Drive Market Growth (19%+ CAGR) - ResearchAndMarkets.com

The "Global PD-1 and PD-L1 Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The PD-1 and PD-L1 inhibitors market will register a CAGR of over 19% by 2023.

Special drug designations to drive the market growth

One of the major benefits that some of the PD-1 and PD-L1 inhibitors have is the special drug designations given by the regulatory bodies. Many of these drugs have received designations such as breakthrough designation and fast track designation from the US FDA, the EMA and other regulatory bodies. Vendors who have received these designations for their molecules will get certain benefits.

Increasing prevalence of cancer

Globe yearly prevalence of cancer has seen a significant rise in recent years, and the global oncology therapeutics market has witnessed the approval of various novel therapies. The gap between the demand and supply of these therapies has resulted in a huge unmet need, which has created an opportunity for vendors to conduct a study on drugs such as PD-1 and PD-L1 inhibitors.

Failures in clinical trials

The global pharmaceuticals market has witnessed a significant increase in the number of trials being conducted for checkpoint inhibitors in recent years. The top six drugs that are currently approved are also in the clinical stages for the treatment of various other cancers.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Merck and Pfizer, the competitive environment is quite intense.

Key Players

  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Comparison by application
  • Solid tumors - Market size and forecast 2018-2023
  • Blood-related tumors - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Merck
  • Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/pl99bc/global_pd1_and?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005559/en/

Editor Details

Last Updated: 07-Feb-2019